- Sort by Popularity (sales)
- Display 15 Products per page
Published: March 1, 2006 | Price: $3,000.00 – $6,000.00
This report on the U.S. market for over-the-counter (OTC) pediatric medications presents an in-depth analysis of the performance of non-prescription pediatric drugs and other selected pediatric healthcare products in the marketplace. The analysis captures the performance of the market players, categories, and leading brands in terms of revenue growth and volume growth in several categories of medication, including cough/cold allergy sinus products; first aid products; internal analgesic products, and other pediatric products (chest rubs, nasal products and bedwetting remedies). In...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research. In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their...Published: February 1, 2006 | Price: $3,000.00 – $6,000.00
The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience solid growth through the end of the decade. This report on the U.S. market for OTC private label products presents an in-depth analysis of the...Published: February 1, 2006 | Price: $1,995.00 – $7,800.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of...Published: February 18, 2006 | Price: $2,200.00 – $5,990.00
Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, along with consumer demand and the move to alternate-site care, are pushing for alternatives to traditional needles and syringes faster than advanced delivery technologies can...Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
The field of biotechnology instrumentation has been an expanding one ever since the emergence of the Human Genome Project 20 years ago. Although the filed certainly existed prior to that point in time, it was the Human Genome Project with its major access to key universities, national laboratories, and government funding sources that gave great acceleration to the field. There are several technologies applicable to genomic and proteomic analysis, all of which have become important to the nature of the...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....Published: January 1, 2006 | Price: $3,000.00 – $6,000.00
The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive report examines all aspects of the U.S. OTC market, including 5-year sales performance by brand and by marketer for the following categories of products: Antifungals...Published: January 1, 2006 | Price: $3,500.00 – $7,000.00
The U.S. long-term care industry experienced strong growth from 1999 through 2004 and this growth is expected to continue through the end of the decade. Indeed, the aging of the U.S. population will push unprecedented demand for all forms of long-term care, but ongoing cost containment issues continue to pressure both private and public managed care organizations and make competition in this dynamic environment challenging. This comprehensive study from Kalorama Information details four segments of the long-term care industry, including:...Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: November 15, 2005 | Price: $2,500.00 – $7,000.00
This completely updated 2nd edition to Kalorama’s popular 2003 study focuses on the market applications of current and advanced drug delivery technology to the development of new and modified pharmaceutical products in the United States. Taking a strategic view of the various therapeutic areas on which drug delivery is anticipated to have its greatest impact, the report considers the options that the current technologies present, the progress that is being made in these fields, and the reception these new products...Published: November 1, 2005 | Price: $3,500.00 – $7,000.00
Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future....Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: November 1, 2005 | Price: $4,995.00 – $9,990.00
There has not been a year in the last decade in which the IVD market in China has failed to grow. With a gross domestic product of over $1.4 trillion, China surpassed Italy last year to become the world’s sixth largest economy, according to the International Monetary Fund. This country of 1.3 billion people is now America’s sixth largest export market, and China’s economy, which has been growing at an average rate of 8% over the last 20 years, grew...